E-Mycin

Gastroparesis, Erythrasma, Whooping Cough + 60 more

Treatment

68 FDA approvals

20 Active Studies for E-Mycin

What is E-Mycin

Erythromycin

The Generic name of this drug

Treatment Summary

Erythromycin is an antibiotic used to treat various bacterial infections. It is a type of macrolide antibiotic, which includes drugs like Azithromycin, Clarithromycin, and Spiramycin. Erythromycin was first discovered in 1952 and can be administered through intravenous, topical, or eye drop preparations.

Erythrocin Stearate

is the brand name

image of different drug pills on a surface

E-Mycin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Erythrocin Stearate

Erythromycin

1964

261

Approved as Treatment by the FDA

Erythromycin, also known as Erythrocin Stearate, is approved by the FDA for 68 uses which include Corynebacterium Infections and Urethritis .

Corynebacterium Infections

Urethritis

Staphylococcus (S.) Aureus Infection

urogenital infections during pregnancy

Pertussis

treponema pallidum infection

Diphtheria

Acne Vulgaris

Used to treat predominant skin comedones, papules and pustules in combination with Tretinoin

penicillins

Bacterial Infections

Communicable Diseases

Conjunctivitis

Respiratory Tract Infections

Erythrasma

Postoperative Infections

Listeriosis

Corynebacterium minutissimum infection

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Pneumonia, Mycoplasma

Whooping Cough

Bordetella Pertussis Infection

uncomplicated endocervical infection

Staphylococcal Skin Infections

Communicable Diseases

Acne Vulgaris

Used to treat Acne Vulgaris in combination with Tretinoin

pustular lesions

Used to treat pustular lesions in combination with Avobenzone

Communicable Diseases

Bacterial Infections

Whooping Cough

Pneumonia

Listeria infection

Listeria monocytogenes infection

Acute Otitis Media caused by Haemophilus Influenzae

Used to treat Acute Otitis Media caused by Haemophilus Influenzae in combination with Sulfisoxazole

inflammatory papular lesions

Used to treat inflammatory papular lesions in combination with Avobenzone

Amebiasis

Common Cold

Rheumatic Fever

prophylaxis of Postoperative Infections

Communicable Diseases

prophylaxis of Rheumatic fever

Ureaplasma urethritis

penicillins

Upper Respiratory Tract Infection

Streptococcus Pneumoniae Infections

Streptococcus pyogenes

Staphylococcal Skin Infections

Urethritis

Urinary Tract Infection (UTI)

Legionella pneumophila

Primary Syphilis

Lower Respiratory Tract Infection (LRTI)

Intestinal amebiasis caused by entamoeba histolytica

Skin and skin structure infections

Corynebacterium Infections

diphtheria antitoxin

Bronchitis

Haemophilus Influenzae Infections

Used to treat Haemophilus Influenzae Infections in combination with null

Urethritis

Ureaplasma urealyticum

skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes

Whooping Cough

Chlamydia Trachomatis

patients with intolerance or contraindications to tetracycline use

Syphilis

First episode of rheumatic fever

Rheumatic Fever

Pneumococcal Infections

Sulfonamides

Effectiveness

How E-Mycin Affects Patients

Erythromycin is an antibiotic used to treat bacterial infections. It works by blocking the production of proteins in bacteria, which stops them from multiplying and spreading. Erythromycin has been shown to be effective against certain bacteria, but it is important to test for drug-resistance before administering the antibiotic. Combining erythromycin with sulfonamides can be effective against resistant Haemophilus influenzae. It is possible to experience side effects such as pseudomembranous colitis and liver dysfunction when taking erythromycin, so it is important to monitor for these symptoms.

How E-Mycin works in the body

Erythromycin works by preventing bacteria from replicating. It does this by interfering with the protein-making process that bacteria need to reproduce. Erythromycin binds to ribosomal RNA molecules, which are necessary for bacterial protein synthesis. By binding to these molecules, it prevents the assembly of the 50S ribosomal subunit, thus halting bacterial protein synthesis. This results in the effective control of various bacterial infections.

When to interrupt dosage

The proposed dosage of E-Mycin is contingent upon the diagnosed condition, including Chlamydia Trachomatis, penicillins and Syphilis. The dose can differ, depending on the means of administration (e.g. Granule, for suspension or Tablet, film coated - Oral) as specified in the table below.

Condition

Dosage

Administration

Amebiasis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Syphilis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Chlamydia Trachomatis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Granuloma Inguinale

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Whooping Cough

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Communicable Diseases

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Corynebacterium Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Primary Syphilis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

First episode of rheumatic fever

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Legionella pneumophila

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Communicable Diseases

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

patients with intolerance or contraindications to tetracycline use

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Urethritis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Pneumonia, Mycoplasma

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Acute Otitis Media caused by Haemophilus Influenzae

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Gastroparesis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Listeriosis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Urethritis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release - Oral, Intravenous, Powder, for solution - Intravenous, Liquid - Oral, Capsule, Capsule - Oral, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Lotion, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Powder, for suspension, Capsule, Delayed Release - Oral, Ointment - Topical, Powder, for solution, Wafer - Oral, Wafer, Kit - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for suspension - Oral, Liquid, Powder, for solution - Oral, Capsule, delayed release pellets - Oral, Powder - Oral, Powder, Capsule, Delayed Release

Warnings

E-Mycin Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Erythromycin may interact with Pulse Frequency

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with E-Mycin.

Common E-Mycin Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Erythromycin.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Erythromycin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Erythromycin.

E-Mycin Toxicity & Overdose Risk

The toxic dose of erythromycin in rats is 9272mg/kg. Overdosing on erythromycin may cause diarrhea, nausea, stomach cramps, and vomiting. If an overdose is suspected, discontinue the drug immediately and seek medical help. Erythromycin cannot be removed from the body using dialysis.

E-Mycin Novel Uses: Which Conditions Have a Clinical Trial Featuring E-Mycin?

Currently, 53 active clinical trials are being conducted to explore the use of E-Mycin to address Streptococcus pyogenes, Treponema pallidum infection and Rheumatic Fever.

Condition

Clinical Trials

Trial Phases

Acne Vulgaris

3 Actively Recruiting

Phase 1, Phase 2, Early Phase 1, Phase 4

Listeriosis

0 Actively Recruiting

Legionella pneumophila

0 Actively Recruiting

Urethritis

0 Actively Recruiting

Ureaplasma urealyticum

0 Actively Recruiting

Acute Otitis Media caused by Haemophilus Influenzae

0 Actively Recruiting

Gastroparesis

14 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Early Phase 1

Acne Vulgaris

0 Actively Recruiting

Pneumococcal Infections

0 Actively Recruiting

Corynebacterium minutissimum infection

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Urethritis

0 Actively Recruiting

Listeria monocytogenes infection

0 Actively Recruiting

Chlamydia Trachomatis

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

penicillins

1 Actively Recruiting

Phase 3

Primary Syphilis

0 Actively Recruiting

treponema pallidum infection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

E-Mycin Reviews: What are patients saying about E-Mycin?

5

Patient Review

7/24/2015

E-Mycin for Middle Ear Infection

This antibiotic was terrible. The abdominal pain it caused was much worse than the flu it was prescribed for. If offered, tell them to try again...

4.7

Patient Review

4/27/2011

E-Mycin for Bacterial Stomach or Intestine Infection caused by Anthrax

Unfortunately, this medication caused me a lot of pain in my stomach. Even when I took it with meals, I experienced cramping and nausea. I had to call my doctor to ask for something different.

4.7

Patient Review

7/12/2012

E-Mycin for Skin Infection

I had some pretty intense cold sweats, nausea and hallucinations.

4.7

Patient Review

5/30/2016

E-Mycin for Skin Infection

I saw results from this treatment within a day, though my appetite decreased while I was taking it.

4

Patient Review

7/28/2015

E-Mycin for Whooping Cough

I experienced zero negative side effects from this treatment!

2

Patient Review

7/13/2015

E-Mycin for Acute Bacterial Infection of the Sinuses

I experienced some serious side effects from this treatment, including cold sweats, dizziness, nausea, and difficulty breathing. My chest felt heavy the entire time.

2

Patient Review

7/7/2009

E-Mycin for Severe Sinusitis caused by Streptococcus Pneumoniae

1

Patient Review

8/15/2022

E-Mycin for Skin Infection

After taking just one pill (with food, as directed), I had such severe stomach cramps, vomiting, and diarrhea. Never again will I choose this treatment over the skin infection it's meant to address.

1

Patient Review

4/9/2013

E-Mycin for Infection of the Middle Ear by S. Pneumoniae Bacteria

Though this drug has helped me to get rid of infections in the past, they always come back a few months later. I also don't seem to experience any side effects, which is great.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about e-mycin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is e-Mycin a penicillin?

"E-Mycin is an antibiotic that is effective against patients with a history of rheumatic disease who are allergic to penicillin antibiotics."

Answered by AI

What does e-Mycin stand for?

"Erythromycin is a type of antibiotic that is used to treat infections caused by bacteria. Erythromycin belongs to a class of drugs called macrolide antibiotics, which work by either killing the bacteria that cause an infection or by stopping the growth of the bacteria."

Answered by AI

Which side effect is common of e-Mycin?

"The serious side effect of this drug is a skin rash. However, other side effects may include severe stomach pain, yellowing of the skin or whites of the eyes, or pale feces with dark urine. These could be signs of problems with the pancreas, liver, or gallbladder."

Answered by AI

What is e-Mycin used to treat?

"It is used to treat certain bacterial infections, to control acne in addition to other acne treatments, and to prevent infections in people with a history of rheumatic disease, congenital heart disease or other acquired valvular heart disease and who are allergic to penicillin antibiotics."

Answered by AI

Clinical Trials for E-Mycin

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Have you considered E-Mycin clinical trials?

We made a collection of clinical trials featuring E-Mycin, we think they might fit your search criteria.
Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA

Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.

Recruiting
Has No Placebo

Children's Community Pediatrics Brentwood (+1 Sites)

Timothy R Shope, MD, MPH

Merck Sharp & Dohme LLC

Image of Maternity Centre of Hamilton in Hamilton, Canada.

Rapid Test for Syphilis

13 - 49
All Sexes
Hamilton, Canada

The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV. The main questions the study aims to answer are: * How often do pregnant people at risk of syphilis agree to the rapid test? * How well do healthcare providers perform the rapid test? * Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners? Participants will: * Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and * Share information about their health, pregnancy, and syphilis treatment (if applicable).

Recruiting
Has No Placebo

Maternity Centre of Hamilton

Laura K Erdman, MD PhD FRCPC

Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA

Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.

Recruiting
Has No Placebo

Benioff Children's Hospital - Oakland (+2 Sites)

Derek J Williams, MD, MPH

Have you considered E-Mycin clinical trials?

We made a collection of clinical trials featuring E-Mycin, we think they might fit your search criteria.
Go to Trials
Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA

The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.

Waitlist Available
Has No Placebo

University of Pennsylvania Primary Care Practice

Have you considered E-Mycin clinical trials?

We made a collection of clinical trials featuring E-Mycin, we think they might fit your search criteria.
Go to Trials